News Breaks |
|
|
| February 26, 2013 |
| 06:45 EDT |  | AMRN | Amarin submits sNDA for Vascepa
Amarin Corporation announced that it has submitted a Supplemental New Drug Application, or sNDA, with the FDA seeking approval for the marketing and sale of Vascepa capsules for use as an adjunct to diet in the treatment of adult patients with high triglycerides with mixed dyslipidemia. Amarin expects to hear within 74 days from the FDA whether the sNDA submission has been accepted for review. |
|
|
News For AMRN From The Last 14 Days Check below for free stories on AMRN the last two weeks. |
|
|
| May 23, 2013 |
| 11:55 EDT |  | AMRN | Options with decreasing implied volatility: AEGR PXP AMRN DSX ACT
 Subscribe for More Information |
|
| May 22, 2013 |
| 11:56 EDT | | AMRN | Options with decreasing implied volatility: WCRX NTI PXP AMRN BBY
|
|
| 06:07 EDT | | AMRN | Amarin announces patent allowance related to combination of Vascepa, Statin
Amarin announced that the United States Patent and Trademark Office has published notification of a Notice of Allowance for Amarin's U.S. Patent Application Serial Number 13/417,899 titled "Pharmaceutical Compositions Comprising EPA and a Cardiovascular Agent and Methods of Using the Same." This application includes claims intended to protect the Vascepa indication approved by the FDA based on Amarin's MARINE clinical trial results specifically those results seen in patients on statin therapy. The claims in this allowed application cover a method to reduce triglycerides in subjects having a triglyceride level of 500mg/dl to 1500mg/dl who are also receiving statin therapy using an amount of Vascepa effective to reduce triglycerides without substantially increasing low density lipoprotein cholesterol. |
|
| May 21, 2013 |
| 11:41 EDT | | AMRN | Options with decreasing implied volatility: SGMO WCRX NTI TSLA AMRN
|
|
| May 17, 2013 |
| 14:12 EDT | | AMRN | Amarin shares slip after FDA updates Orange Book
Subscribe for More Information |
|
| May 15, 2013 |
| 11:04 EDT |  | AMRN | Amarin management to meet with Lazard Capital
Meeting to be held in the Mid-Atlantic area on May 16 hosted by Lazard Capital. |
|
| May 13, 2013 |
| 12:52 EDT | | AMRN | Amarin strength attributed to MassHealth drug list addition
Subscribe for More Information |
|
|
|
|
|
